Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 203

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 203
---
 set forth in the unaudited pro forma combined financial information are described in the accompanying notes. The unaudited pro forma combined financial information has been presented for illustrative purposes only and is not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the dates indicated, and does not reflect adjustments for any anticipated synergies, operating efficiencies, tax savings or cost savings. Any cash proceeds remaining after the consummation of the Business Combination and the other events contemplated by the Business Combination Agreement are expected to be used for general corporate purposes. Further, the unaudited pro forma combined financial

<div align='center'>89</div>

TABLE OF CONTENTS

information does not purport to project the future operating results or financial position of the Combined Company following the consummation of the Business Combination. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of the unaudited pro forma combined financial information and are subject to change as additional information becomes available and analyses are performed. The unaudited pro forma combined financial information contained herein assumes that the Iris stockholders approve the Business Combination. Pursuant to the Iris Certificate of Incorporation, the Iris public stockholders may elect to redeem their Iris common shares upon the closing of the Business Combination for cash equal to their pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the Trust Account. Iris cannot predict how many of its public stockholders will exercise their right to redeem their Iris common stock for cash. Therefore, the unaudited pro forma combined financial information present two redemption scenarios as follows: • Assuming No Additional Redemptions — this scenario assumes that no additional Public Stockholders of IRIS exercise redemption rights with respect to their Iris common shares; and • Assuming Maximum Redemptions — this scenario assumes that 174,477 Iris common shares are redeemed at approximately $11.09 per share for an aggregate payment of approximately $1.9 million (includes market appreciation and interest on the marketable securities and/or balances held in the Trust Account as of September 30, 2024). The two redemption scenarios assumed in the unaudited pro forma combined balance sheet and statement of operations do not include adjustments for the outstanding private warrants issued in connection with Iris’s initial public offering, as such these securities are not exercisable until 30 days after the Closing. The following summarizes the pro forma common shares issued and outstanding immediately after the Business Combination:

| ​                                                |